ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress

Abstract Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy. While this is an important treatment option, many patients fail to ach...

Full description

Bibliographic Details
Main Authors: Jenna L. Carter, Yongwei Su, Eman T. Al-Antary, Jianlei Zhao, Xinan Qiao, Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Steven A. Buck, Maik Hüttemann, Joshua E. Allen, Varun V. Prabhu, Jay Yang, Jeffrey W. Taub, Yubin Ge
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Acute myeloid leukemia
Venetoclax
Azacitidine
ONC213
Online Access:https://doi.org/10.1186/s13046-024-03267-6

Internet

https://doi.org/10.1186/s13046-024-03267-6

Similar Items